Amplification of the EMSY gene in sporadic breast and ovarian cancers is a poor prognostic indicator. Although EMSY has been linked to transcriptional silencing, its mechanism of action is unknown. Here, we report that EMSY acts as an oncogene, causing the transformation of cells invitro and potentiating tumor formation and metastatic features invivo. Weidentify an inverse correlation between EMSY amplification and miR-31 expression, an antimetastatic microRNA, in the METABRIC cohort of human breastsamples. Re-expression of miR-31 profoundly reduced cell migration, invasion, and colony-formation abilities of cells overexpressing EMSY or haboring EMSY amplification. We show that EMSY is recruited to the miR-31 promoter by the DNA binding factor ETS-1, and it represses miR-31 transcription bydelivering the H3K4me3 demethylase JARID1b/PLU-1/KDM5B. Altogether, these results suggest a pathway underlying the role of EMSY in breast cancer and uncover potential diagnostic and therapeutic targets in sporadic breast cancer. © 2014 The Authors.
CITATION STYLE
Viré, E., Curtis, C., Davalos, V., Git, A., Robson, S., Villanueva, A., … Kouzarides, T. (2014). The breast cancer oncogene EMSY represses transcription of antimetastatic microRNA miR-31. Molecular Cell, 53(5), 806–818. https://doi.org/10.1016/j.molcel.2014.01.029
Mendeley helps you to discover research relevant for your work.